Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions - Wikidata - awgldk - TriplyDB

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

http://www.wikidata.org/entity/Q37226245

about

Nonsteroidal anti-inflammatories (NSAIDs) and aspirin for intestinal metaplasia of the stomach Gastric cancer: prevention, screening and early diagnosis Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portu Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors Follow-up of intestinal metaplasia in the stomach: When, how and why.The prevention of infection-associated cancers Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.Cyclooxygenase-2 and gastric cancer.Role of cyclooxygenase-2 in gastric cancer development and progression.The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.Adding diclofenac to Helicobacter pylori eradication regimen.Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.miR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells.Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions.Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portug

P2860

Q24235197-1B67E57F-1C59-43AB-9946-04D5BBC5B4D7 Q26860418-89BBE91E-90F7-4A26-B655-EB6A0EA02A87 Q30426539-5A74513E-EF7D-4E40-ADD6-4B2F20C9C1A8 Q34369331-A38B0A81-6BB8-4DD0-ABFD-A5003DB67079 Q35854490-4582F36D-AD01-46A0-90FD-34E321EDBEE9 Q35857515-0A7BD175-B2CF-4F56-A281-546EAF6B44FE Q37394555-C5BE804D-D91A-408E-9BEA-C866AEEEDF95 Q37946290-06F0403D-C0B9-4E81-8454-F76BC5961535 Q38164703-8D5A64BE-9E04-4D31-98D6-3FEEB53A935F Q39273352-ED327225-B017-4772-BA6B-342D04BC0AC1 Q41024354-A4D0FDF4-5286-488C-845D-7878C01EAB6B Q41589499-5D58AB30-DA9D-422A-9DA4-82D3F35DEE83 Q43181472-2EF3C104-367E-468A-ADEF-FF3AB07F2F9B Q50129416-4FDB5F96-34D3-4A9D-8745-8B08DD624593 Q55194995-11A1D442-3DA8-4C27-8B8C-282FAFA4ED53 Q57698678-615243DB-65BA-434B-8C99-6B54288AF8B7

P2860

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

http://www.wikidata.org/entity/Q37226245

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-Helicobacter pylori thera ...... f gastric precancerous lesions

@en

Anti-Helicobacter pylori thera ...... gastric precancerous lesions.

@nl

type

label

Anti-Helicobacter pylori thera ...... f gastric precancerous lesions

@en

Anti-Helicobacter pylori thera ...... gastric precancerous lesions.

@nl

prefLabel

Anti-Helicobacter pylori thera ...... f gastric precancerous lesions

@en

Anti-Helicobacter pylori thera ...... gastric precancerous lesions.

@nl

P1433

Q37226245-98137E30-203D-4433-A15F-4C0BC1B75F45

P1476

Q37226245-71566315-4DBB-467A-913D-5411465D67D8

P2093

Q37226245-255E06CC-D744-4BCD-9140-E31BF85458BF

Q37226245-56CC2C66-4849-4411-A698-0236446AC105

Q37226245-590A560B-8C4B-4277-B4F1-259D7D7BC61D

Q37226245-78AB244E-1AA0-480C-BDC1-F35CFA597190

Q37226245-9A9FE8AB-B44F-4A2F-AB25-5A1DEA226CB5

Q37226245-BD3C78A7-236E-4CFA-AA06-E0D791F9DC26

Q37226245-C0A014C4-779C-4CD5-BE61-771C411EDA5D

Q37226245-E1533A13-3FA9-476D-9113-E7EFEFBE4484

Q37226245-E23CF4A2-9441-413D-ACC2-6F5302B0CCB1

Q37226245-F0F72370-C4E8-48AF-8755-D90D42AA75A7

P2860

Q37226245-03DA6AB0-B1C7-4D67-B79F-26D6B3A8082F

Q37226245-0B1F7F84-4080-4ADB-857E-E4CB70403466

Q37226245-0B8F3E6B-3F76-435C-A7E4-286656A1E193

Q37226245-120C19A5-653F-464D-B677-3C775B1CB5ED

Q37226245-139253B9-AD35-48AE-B8D9-6AE7A15E26F1

Q37226245-1753D66B-7871-485A-ACA6-98EF4DC2643E

Q37226245-179E3C60-888B-4C84-9671-D12CE18D46C9

Q37226245-24A6F1B6-A04A-4C7D-80DB-AF16ADB882EB

Q37226245-2604F144-70E0-4422-9C8D-865E401A7182

Q37226245-2C7CC0C5-151A-4749-817D-6D212623BBAA

P304

Q37226245-9671B5FD-DFE9-417C-8750-1629CC2E1DD9

P31

Q37226245-02BC8B07-59EC-4ED3-816E-F2B44F43F7EF

P356

Q37226245-610628BC-5E22-4392-A091-DA06BD7A9105

P407

Q37226245-ABBA95F6-B371-4D75-9688-02C5C58FA931

P433

Q37226245-00D448E9-5B37-48CC-BF9C-13B3DCE402DF

P478

Q37226245-795B1FB7-4522-4DD3-810C-C3FD8D1D1E1C

P577

Q37226245-29C0D190-131D-4269-B69C-6EE0D508A04A

P698

Q37226245-9A39DF14-50F1-4AEB-BE10-DF91289C27CE

P921

Q37226245-45D43A7D-AE79-47BD-A2E4-944B9AE2B02A

P932

Q37226245-6AD0844A-531D-4340-A9E2-F821BBF1A860

P356

P1433

World Journal of Gastroenterology

P1476

Anti-Helicobacter pylori thera ...... f gastric precancerous lesions

@en

P2093

Dong-Sheng Cui

http://www.w3.org/2001/XMLSchema#string

Jian-Kun Chu

http://www.w3.org/2001/XMLSchema#string

Jin-Cheng Ma

http://www.w3.org/2001/XMLSchema#string

Jun Yu

http://www.w3.org/2001/XMLSchema#string

Li-Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Ming-Wei Wang

http://www.w3.org/2001/XMLSchema#string

Ping Gu

http://www.w3.org/2001/XMLSchema#string

Shi-Yan Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Hui Huo

http://www.w3.org/2001/XMLSchema#string

Zeng-Ren Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation

Cyclooxygenase-2 and gastric carcinogenesis

Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells

15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.

Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.

Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.

Estimating the world cancer burden: Globocan 2000.

Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?

Cyclooxygenase-2: a therapeutic target in angiogenesis.

P304

2731-2738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.15.2731

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19522023

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori

P932

2695888

http://www.w3.org/2001/XMLSchema#string